July 18, 2018
With the relocation of their headquarters to Cambridge, MA, Ipsen US is entering a new era of innovation and growth to become a leading global biotech company in the therapeutic areas of oncology, neuroscience, and rare disease. With this evolution of their business, Ipsen US has retained The Chase Group to secure a Vice President, Neurology Business Unit to join their executive leadership team. In a crowded and highly competitive market, Ipsen US values talent who are fearless, resourceful, and driven to succeed in an entrepreneurial and collaborative culture. The Chase Group appreciates and values our continued partnership with Ipsen US and is privileged to secure high caliber talent to help improve the lives of patients with the most serious and rare diseases.